FML539 / Novartis - LARVOL DELTA

[177Lu]Lu-DWJ155 (FML539), a novel HER2-targeting radioligand therapy for the treatment of HER2-low and HER2-positive breast cancer (BC) and HER2-expressing non-small cell lung cancer (NSCLC). (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=156 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Bladder Cancer • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2